全文获取类型
收费全文 | 415篇 |
免费 | 17篇 |
国内免费 | 6篇 |
专业分类
儿科学 | 14篇 |
基础医学 | 35篇 |
口腔科学 | 6篇 |
临床医学 | 74篇 |
内科学 | 131篇 |
皮肤病学 | 5篇 |
神经病学 | 13篇 |
特种医学 | 47篇 |
外科学 | 62篇 |
综合类 | 3篇 |
预防医学 | 24篇 |
眼科学 | 1篇 |
药学 | 9篇 |
肿瘤学 | 14篇 |
出版年
2022年 | 3篇 |
2020年 | 3篇 |
2019年 | 7篇 |
2018年 | 13篇 |
2017年 | 6篇 |
2016年 | 2篇 |
2015年 | 3篇 |
2014年 | 7篇 |
2013年 | 17篇 |
2012年 | 12篇 |
2011年 | 13篇 |
2010年 | 17篇 |
2009年 | 15篇 |
2008年 | 22篇 |
2007年 | 42篇 |
2006年 | 9篇 |
2005年 | 19篇 |
2004年 | 14篇 |
2003年 | 8篇 |
2002年 | 4篇 |
2001年 | 8篇 |
2000年 | 4篇 |
1999年 | 7篇 |
1998年 | 12篇 |
1997年 | 12篇 |
1996年 | 19篇 |
1995年 | 13篇 |
1994年 | 15篇 |
1993年 | 15篇 |
1992年 | 4篇 |
1990年 | 3篇 |
1989年 | 9篇 |
1988年 | 10篇 |
1987年 | 9篇 |
1986年 | 8篇 |
1985年 | 9篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1981年 | 4篇 |
1980年 | 6篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1959年 | 2篇 |
1949年 | 1篇 |
1931年 | 1篇 |
1919年 | 1篇 |
1889年 | 1篇 |
排序方式: 共有438条查询结果,搜索用时 31 毫秒
1.
2.
Membranes that exclude water but are permeable to radon can extend the range of environments where many radon detection systems could operate. We have studied the permeation of 222Rn through polypropylene membranes separating air and water phases. The permeation coefficient and the activation energy were calculated for various conditions. Potential applications, such as in situ detection of radon in water, are discussed. 相似文献
3.
4.
Osteoarthritis is a whole joint disease involving cartilage, synovial tissue, sub-chondral bone, ligaments, muscles, and tendons. Non-pharmacological and pharmacological treatments for knee osteoarthritis target specifically these different tissue structures. Mechanical stress is the main actor in non-pharmacological treatment modalities. Muscle strengthening is able to decrease overload on symptomatic joint compartment, increase the stability of the knee, and probably decrease local inflammation. 相似文献
5.
S. Rannou N. Guirimand L. Cartron F. Tresvaux du Fraval Y. Sahbatou J. -L. Lagrange G. Benoît A. Leplège C. Besson 《Psycho-Oncologie》2011,5(4):227-234
In 2006, a framework for cancer diagnosis disclosure was defined in the French Cancer Plan. In a study supported by the Ligue contre le cancer and the Institut national du cancer, we evaluated the impact of this measure on the quality of life of 29 cancer patients. The study was conducted in two hospitals of the South Île-de-France, between 2006 and 2010. The role of a nurse in diagnosis disclosure appears beneficial. Limiting the number of present caregivers, proposing the presence of a relative during the diagnosis disclosure or the systematic proposal of a psychological support also seems important. Developing the knowledge of doctors on communicating bad news also appears crucial. 相似文献
6.
Deeg HJ; Storb R; Thomas ED; Flournoy N; Kennedy MS; Banaji M; Appelbaum FR; Bensinger WI; Buckner CD; Clift RA 《Blood》1985,65(6):1325-1334
Seventy-five patients, 13 to 49 years of age, with acute nonlymphoblastic leukemia in first remission were treated with cyclophosphamide, fractionated total body irradiation, and marrow transplantation from an HLA-identical sibling and randomized to receive either cyclosporine (CSP) (n = 36) or methotrexate (MTX) (n = 39) as prophylaxis for graft-v-host disease (GVHD). All patients engrafted, and 22 who were given CSP and 21 who were given MTX, are alive at 20 to 47 (median, 35) months (P = .5). Engraftment as assessed by granulocyte recovery (P less than .0005) and platelet transfusion requirement (P = .01) was faster in patients on CSP. Twelve patients (33%) on CSP and 22 (56%) on MTX developed acute GVHD of grades II through IV (P = .07) and 15 of 30 on CSP and 14 of 32 on MTX that were at risk developed chronic GVHD. The most frequent causes of death were interstitial pneumonitis and marrow relapse of leukemia, which occurred with similar frequency in both groups. Beneficial effects observed in patients on CSP included less severe mucositis and shorter duration of hospitalization; adverse effects included renal function impairment and hypertension. These data confirm that CSP is a useful immunosuppressant in patients undergoing marrow transplantation but fail to show a significant improvement in survival as compared with the standard regimen of MTX. 相似文献
7.
Camille Daste François Rannou Luc Mouthon Katherine Sanchez Alexandra Roren Vincent Tiffreau Éric Hachulla Philippe Thoumie Jean Cabane Emmanuel Chatelus Jean Sibilia Serge Poiraudeau Christelle Nguyen 《Seminars in arthritis and rheumatism》2019,48(4):694-700
Background
To estimate patient acceptable symptom state (PASS) and minimal clinically important difference (MCID) for patient-reported outcomes in systemic sclerosis (SSc).Methods
We conducted a secondary analysis of the SCLEREDUC trial, a 12-month randomized controlled trial comparing the efficacy of physical therapy to usual care in 220 SSc patients followed-up from September 2005 to October 2010. Self-rated state and change in patient health at 12 months were assessed by using 2 external anchors extracted from the Medical Outcomes Study 36-Item Short-Form. Patients who self-rated their health as “excellent”, “very good” or “good” were the PASS group and those who self-rated their health change as “somewhat better” were the MCID group. Main outcomes were the estimates of PASS by using the 75th percentile method and of MCID by using the mean change in scores method for pain and activity limitation.Results
PASS (95% confidence interval) and mean (SD) MCID estimates at 12 months were 53.75 (34.00 to 68.00) and ?6.74 (32.02) for the joint-pain visual analog scale (range 0–100), 1.41 (1.13 to 1.63) and ?0.21 (0.48) for the Health Assessment Questionnaire (HAQ, range 0–3), 1.27 (1.07 to 1.62) and ?0.13 (0.45) for the scleroderma HAQ (range 0–3), 26.00 (17.00 to 37.00) and -3.38 (9.87) for the Cochin Hand Function Scale (range 0–90), and 19.40 (17.20 to 21.90) and ?5.69 (6.79) for the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire (range 0–30), respectively.Conclusions
We provide, for the first time, the PASS and MCID estimates for pain and activity limitation in SSc.8.
Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia 总被引:1,自引:1,他引:1
Robinson N; Sanders JE; Benyunes MC; Beach K; Lindgren C; Thompson JA; Appelbaum FR; Fefer A 《Blood》1996,87(4):1249-1254
Allogeneic bone marrow transplantation (BMT) for advanced acute leukemia is associated with a high risk of relapse. It is postulated that interleukin-2 (IL-2) administered after BMT might induce or amplify a graft-versus-leukemia effect and thereby reduce the relapse rate. To identify an IL-2 regimen for testing this hypothesis, a phase I trial of IL-2 (Roche) was performed in children in complete remission (CR) without active graft-versus-host disease (GVHD) off immunosuppressive agents after unmodified allogeneic matched-sibling BMT for acute leukemia beyond first remission. Beginning a median of 68 days after BMT, 17 patients received escalating doses of induction IL-2 (0.9, 3.0, or 6.0 x 10(6) IU/m2/d representing levels I, II, and III) for 5 days by continuous intravenous infusion (CIV). After 6 days of rest, they received maintenance IL-2 (0.9 x 10(6) IU/m2/d) for 10 days by CIV infusion. Levels I and II were well-tolerated, but, of 6 patients at level III, 1 developed pulmonary infiltrates, 1 developed hypotension (both resolved), and 1 died of bacterial sepsis and acute respiratory distress syndrome. Grade II acute GVHD developed in 1 patient at level I and 1 at level III. The maximum tolerated dose of induction IL-2 was level II. IL-2 induced lymphocytosis, with an increase in CD56+ and CD8+ cells. Ten patients remain in CR at 5+ to 67+ months. Thus, a regimen of IL-2 has been identified that did not induce a high incidence of acute GVHD when administered to children after unmodified allogeneic BMT. Its clinical activity will be assessed in a phase II trial. 相似文献
9.
Charlotte Pauwels Alexandra Roren Adrien Gautier Jonathan Linières François Rannou Serge Poiraudeau Christelle Nguyen 《Annals of physical and rehabilitation medicine》2018,61(3):144-150
Background
Lumbar-flexion-based endurance training, namely cycling, could be effective in reducing pain and improving function and health-related quality of life in older people with chronic low back pain.Objectives
To assess barriers and facilitators to home-based cycling in older patients with lumbar spinal stenosis (LSS).Methods
We conducted a retrospective mixed-method study. Patients ≥ 50 years old followed up for LSS from November 2015 to June 2016 in a French tertiary care center were screened. The intervention consisted of a single supervised session followed by home-based sessions of cycling, with dose (number of sessions and duration, distance and power per session) self-determined by patient preference. The primary outcome was assessed by a qualitative approach using semi-structured interviews at baseline and 3 months and was the identification of barriers and facilitators to the intervention. Secondary outcomes were assessed by a quantitative approach and were adherence monitored by a USB stick connected to the bicycle, burden of treatment assessed by the Exercise Therapy Burden Questionnaire (ETBQ) and clinical efficacy assessed by change in lumbar pain, radicular pain, disability, spine-specific activity limitation and maximum walking distance at 3 months.Results
Overall, 15 patients were included and data for 12 were analyzed at 3 months. At baseline, the mean age was 70.9 years (95% CI: 64.9–76.8) and 9/15 patients (60.0%) were women. Barriers to cycling were fear of pain and fatigue, a too large bicycle, burden of hospital follow-up and lack of time and motivation. Facilitators were clinical improvement, surveillance and ease-of-use of the bicycle. Adherence remained stable overtime. The burden of treatment was low [mean ETBQ score: 21.0 (95% confidence interval: 11.5–30.5)]. At 3 months, 7/12 patients (58.3%) self-reported clinical improvement, with reduced radicular pain and disability [mean absolute differences: ?27.5 (?43.3 to ?11.7), P < 0.01 and ?17.5 (?32.1 to ?2.9), P = 0.01, respectively].Conclusions
For people with LSS, home-based cycling is a feasible intervention. 相似文献10.
Bensinger WI; Weaver CH; Appelbaum FR; Rowley S; Demirer T; Sanders J; Storb R; Buckner CD 《Blood》1995,85(6):1655-1658
Peripheral blood stem cells (PBSCs) are widely used in autologous transplantation because of ease of collection and rapid hematopoietic reconstitution. However, PBSCs have rarely been used for allogeneic transplantation because of concerns about donor toxicities from cytokine administration and the theoretical increased risk of graft- versus-host-disease (GVHD) from the large number of T cells infused. Eight patients with advanced malignancies received allogeneic PBSC transplants from genotypically HLA-identical sibling donors. All donors received 5 days of recombinant human granulocyte colony-stimulating factor (rhG-CSF; 16 micrograms/kg/day) subcutaneously and were leukapheresed for 2 days. After treatment of the patient with total body irradiation and cyclophosphamide (n = 7) or etoposide, thiotepa, and cyclophosphamide (n = 1), PBSCs were infused immediately after collection and without modification. All patients received cyclosporine and either methotrexate (n = 6) or prednisone (n = 2) for GVHD prophylaxis, rhG-CSF was well tolerated with mild bone pain requiring acetaminophen occurring in two donors. All patients engrafted and in seven hematopoietic recovery was rapid, with 500 neutrophils/microL achieved by day 18 and 20,000 platelets/microL by day 12. Complete donor engraftment was documented by Y chromosome analysis in all four sex-mismatched donor-recipient pairs tested and by DNA analysis in two sex-matched pairs. One patient died on day 18 of veno-occlusive disease of the liver with engraftment but before chromosome analysis could be performed (results are pending in 1 patient). A second patient died of fungal infection 78 days after transplant. Grade 2 acute GVHD occurred in two patients and grade 3 GVHD occurred in one patient. One patient is 301 days from transplant in remission with chronic GVHD; the remaining five patients are alive and disease free 67 to 112 days after transplantation. Preliminary results indicate that allogeneic PBSCs mobilized by rhG-CSF can provide rapid hematologic recovery without an appreciably greater incidence of acute GVHD than would be expected with marrow. Further follow-up is required to determine the incidence of chronic GVHD and any potential beneficial effects on relapse after transplant. 相似文献